Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone305-420-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
Employees51
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions
What is Catalyst Pharmaceuticals' stock symbol?
Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced its quarterly earnings data on Monday, May, 13th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.12. The biopharmaceutical company earned $12.45 million during the quarter, compared to the consensus estimate of $2.40 million. During the same period in the previous year, the business posted ($0.06) earnings per share. View Catalyst Pharmaceuticals' Earnings History.
When is Catalyst Pharmaceuticals' next earnings date?
What price target have analysts set for CPRX?
4 brokers have issued twelve-month price targets for Catalyst Pharmaceuticals' shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $8.1250 in the next year. This suggests a possible upside of 113.8% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals.
What is the consensus analysts' recommendation for Catalyst Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals.
What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?
Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Catalyst reported narrower-than-expected loss and sales beat estimates in the first quarter of 2019. Firdapse is the company’s first approved product. The drug is the first FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, which was approved in November 2018 and launched in January. The company generated entire first-quarter revenues from Firdapse. Catalyst is also developing Firdapse to treat additional rare neuromuscular diseases. However, all the other candidates in its portfolio are in early stages of development. Thus, the successful development and commercialization of drug candidates are highly crucial for the company. Shares of the company have outperformed the industry year to date." (5/21/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and PT of $10 per share of CPRX. the FDA approved private company the treatment of LEMS in pts 6 to <17 years of age. This is the first drug approved for pediatric LEMS. However, Catalyst's slighty different salt form of amifampridine, marketed as Firdapse, was the first drug approved for LEMS, but for adults only. We were surprised by this announcement as no clinical studies were conducted in the pediatric population that we are aware of, and the approval relied on studies of the drug in adults with LEMS, including PK data that were then modeled/extrapolated to identify the dosing regimen in pediatric pts."" (5/7/2019)
- 3. HC Wainwright analysts commented, "We raised our PT to $9 from $6 in view of the additional color on the commercial front. We adjusted the launch cost of and lowered the peak penetration from 25% to 18%." (12/14/2018)
Has Catalyst Pharmaceuticals been receiving favorable news coverage?
Media coverage about CPRX stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Catalyst Pharmaceuticals.
Who are some of Catalyst Pharmaceuticals' key competitors?
Some companies that are related to Catalyst Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), Cambrex (CBM), Innoviva (INVA), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Apellis Pharmaceuticals (APLS), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Athenex (ATNX), Corcept Therapeutics (CORT), Phibro Animal Health (PAHC), Opko Health (OPK) and Eidos Therapeutics (EIDX).
What other stocks do shareholders of Catalyst Pharmaceuticals own?
Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the folowing people:
- Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)
- Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)
- Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)
- Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)
- Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63)
Who are Catalyst Pharmaceuticals' major shareholders?
Catalyst Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Kennedy Capital Management Inc. (0.97%), Knott David M (0.50%), EAM Global Investors LLC (0.27%), Alps Advisors Inc. (0.24%), Lido Advisors LLC (0.12%) and Rhumbline Advisers (0.12%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals.
Which major investors are selling Catalyst Pharmaceuticals stock?
Which major investors are buying Catalyst Pharmaceuticals stock?
CPRX stock was bought by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., EAM Global Investors LLC, Ibex Investors LLC, FNY Investment Advisers LLC, BNP Paribas Arbitrage SA, Biltmore Capital Advisors LLC, Lido Advisors LLC and Alps Advisors Inc.. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals.
How do I buy shares of Catalyst Pharmaceuticals?
Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Pharmaceuticals' stock price today?
One share of CPRX stock can currently be purchased for approximately $3.80.
How big of a company is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals has a market capitalization of $390.83 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-34,000,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.View Additional Information About Catalyst Pharmaceuticals.
What is Catalyst Pharmaceuticals' official website?
How can I contact Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]
MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
